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Abstract
The European Union’s attention to the problem of antibacterial resistance will soon reach a 10-year mark, but the rates of resistance
in Gram-positive and Gram-negative bacteria are still increasing. This review focuses on the clinical impact of resistant Gram-positive
bacteria on patients. Multiple drug resistance in pneumococcal infections will lead to more treatment failures and higher mortality,
which so far have been seen with penicillins and pathogens with high-level resistance. Several studies have demonstrated higher mortal-
ity, prolonged length of hospital stay and higher costs associated with methicillin-resistant Staphylococcus aureus infections, in comparison
with methicillin-susceptible Staphylococcus aureus infections. Similarly, vancomycin-resistant enterococci bloodstream infections have a
negative impact with respect to mortality, length of hospital stay and costs, in comparison with infections due to vancomycin-susceptible
enterococci. Several distinctive prophylactic and therapeutic approaches have to be undertaken to successfully prevent the clinical con-
sequences of antibiotic resistance in Gram-positive bacteria. This review addresses the impact of antibiotic-resistant Gram-positive
pathogens on clinical outcomes.
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Introduction
The European Union’s attention to the nightmare of anti-
microbial resistance will soon reach a 10-year mark [1].
Available evidence shows that the proportion of Gram-posi-
tive bacteria resistant to commonly used antibiotics is
increasing [2,3]. The mechanisms of this resistance are often
complex, and include production of b-lactamases, upregulat-
ed efﬂux pumps, and target site mutations [4,5]. Raising
awareness of the effect of antimicrobial resistance on clinical
outcomes has several potential beneﬁts [6]. Knowledge
about the implications of resistance for patient outcomes
may prompt hospitals and healthcare providers to establish
and support initiatives to prevent such infections. Suscepti-
bility data can be used to convince healthcare providers to
follow guidelines concerning isolation and to make rational
choices about the use of antimicrobial agents. Furthermore,
susceptibility data can guide policy-makers, i.e. those respon-
sible for decisions concerning funding of programmes, to
track and prevent the spread of antimicrobial-resistant
organisms. Finally, such awareness may stimulate interest in
developing new antimicrobial agents and therapies.
Various methodological issues can inﬂuence the carrying
out and the results of studies of antimicrobial resistance out-
comes [7]. The types of outcome considered, the perspec-
tive of the study, the reference groups within the study, the
adjustments for confounding factors and the type of eco-
nomic assessment are among the factors that should be
taken into account (Table 1) [8].
Streptococcus Pneumoniae
The global ﬁgures concerning morbidity and mortality due to
pneumococcal pneumonia, the most common type of com-
munity-acquired pneumonia (CAP), remain striking [9]. The
mortality rate ranges from 6.4% among patients in an ambu-
latory and hospital setting to >40% among patients treated in
an intensive-care unit (ICU). Historically, clinicians have pre-
scribed penicillin for the empirical treatment of S. pneumoniae
infections, with little concern about the susceptibility of the
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pneumococcus to the chosen antimicrobial. However, the
development of multidrug resistance among clinical S. pneumo-
niae isolates has posed more challenges in treating some syn-
dromes caused by this organism. ‘High-level’ penicillin
resistance (MIC‡2.0 mg/mL) among S. pneumoniae has
increased to a greater degree during the past 10 years than
has intermediate resistance. Despite the decreasing suscepti-
bility of pneumococci to penicillin, convincing evidence that
resistance has an adverse effect on clinical outcomes, partic-
ularly mortality, is lacking [10]. This was illustrated in a pro-
spective 10-year study from Spain, in which mortality was
not found to correlate with drug resistance, even though
rates of resistance to penicillin, cephalosporins and erythro-
mycin increased during the study period [11]. Since then,
several studies have attempted to evaluate this relationship.
In a review of the implications of antibacterial resistance for
the treatment of CAP, Metlay [12] evaluated 15 published
reports assessing the impact of penicillin-non-susceptible
S. pneumoniae (PNSSP) on outcomes of pneumococcal pneu-
monia, representing the outcomes of >7500 patients. Twelve
of the studies concluded that non-susceptibility had no
impact on mortality.
However, in several studies, treatment and severity of ill-
ness were not recorded. In a trial controlling for risk factors,
severity of illness and treatment, the ﬁndings revealed that
antimicrobial resistance did not contribute to mortality or to
the requirement for ICU care, and revealed that more
important predictors of outcome included severity of illness
[13]. An international prospective, observational study of
844 patients with pneumococcal bacteraemia revealed that
age, severity of illness and comorbidity were associated with
mortality but not with the isolates being PNSSP [14]. In sum-
mary, the prevailing view has been that current levels of pen-
icillin resistance do not adversely affect outcomes of CAP in
immunocompetent patients as long as the MIC is <4.0 mg/L
(which is the case for the majority of non-susceptible
isolates).
In the latest analysis of penicillin resistance by Tleyjeh
et al. [15], ten studies that fulﬁlled very rigorous criteria
were identiﬁed out of 1152 articles and were evaluated. The
authors examined the association between PNSSP and short-
term mortality in pneumococcal pneumonia, and found a sig-
niﬁcant difference in the mortality rate (19.4% in the PNSSP
group and 15.7% in the penicillin-susceptible S. pneumoniae
group) (Table 2). They concluded that penicillin non-suscepti-
bility is a prognostic factor and should be included as a risk
factor for mortality. If this observation is correct, it calls for
a change in our view of PNSSP and implies an increased need
to address the issue of penicillin resistance [9]. However,
the authors’ ability to control for confounding variables in
TABLE 1. Methodological factors with inﬂuence on studies
assessing the impact of infection with antimicrobial-resistant
bacteria ([6], reprinted with permission)
Methodological
issue, factor Aspects
Outcome
Mortality In hospital, attributable to infection; in
hospital and after discharge, all-cause
Morbidity Length of hospitalization, need for ICU care,
need for surgery or other procedures,
activity level at discharge, and loss of
functional status (loss of work)
Economic Hospital costs, hospital charges, resource
utilization, total healthcare costs, skilled
nursing, and other outpatient costs
Other perspective
Hospital Inpatient morbidity, mortality, and/or costs
Third-party payer Inpatient and outpatient healthcare costs
Patient Decreased functional status, loss of work,
and fewer antimicrobial agent options
Societal Total healthcare costs of antimicrobial
resistance and loss of antimicrobial classes
Choice of reference group
Patients infected with
susceptible strains
–
Uninfected patients –
Patients colonized with
resistant strains
–
Confounding factors
Length of hospital stay APACHE score, McCabe/Jackson score, and
Charlson comorbidity score
Underlying severity of
illness
–
Comorbid conditions –
ICU, intensive-care unit.
TABLE 2. Summary of combined relative risks (RRs) of mortality for the penicillin-non-susceptible Streptococcus pneumoniae
(PNSSP), penicillin-intermediate S. pneumoniae (PISP) and penicillin-resistant S. pneumoniae (PRSP) groups, compared with
the penicillin-susceptible S. pneumoniae (PSSP) group ([15], reprinted with permission)
PNSSP group PISP group PRSP group
Group
No. of
studies
No. of
patients RR (95% CI)
No. of
studies
No. of
patients RR (95% CI)
No. of
studies
No. of
patients RR (95% CI)
Total cohort 10 1140 1.31 (1.08–1.59) 10 707 1.34 (1.13–1.60) 10 433 1.29 (1.01–1.66)
Bacteraemic group 5 545 1.50 (1.22–1.84) 5 327 1.61 (1.28–2.03) 5 218 1.38 (0.99–1.93)
Concordant therapy group 5 293 1.60 (1.07–2.40) 5 218 1.54 (0.99–2.41) 5 75 1.84 (1.15–2.97)
Discordant therapy group 5 164 1.61 (1.12–2.31) 5 91 1.72 (1.10–2.70) 5 73 1.88 (1.15–3.08)
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each of the analysed studies can be questioned, as it is well
recognized that mortality associated with pneumococcal
pneumonia often reﬂects factors that are independent of
antimicrobial susceptibility. Host factors (e.g. extremes of
age, underlying immunosuppressive or debilitating diseases
and comorbidities, or factors intrinsic to the microorganisms,
e.g. capsular subtypes) inﬂuence mortality irrespective of
antimicrobial susceptibility proﬁles [16–18]. Mortality rates
are higher in the presence of multilobar involvement, renal
insufﬁciency, hypoxaemia, severe irregularities in physiological
parameters, and other comorbidities, as well as ICU stay.
Macrolide resistance in S. pneumoniae may have a higher
clinical importance than penicillin resistance. Several authors
have reported failures of macrolide treatment in patients
with bacteraemia due to macrolide-resistant S. pneumoniae
[19–21]. In studies from the USA and Europe, cases of
‘breakthrough’ bacteraemia were reported during macrolide
treatment [22,23], but nearly all patients were treated suc-
cessfully with other antibiotics [21,23]. Also, some data sug-
gest that resistance to older ﬂuoroquinolones can result in
clinical failure [24].
Staphylococcus Aureus
Since its ﬁrst appearance in 1960 [25], methicillin resistance
in Staphylococcus aureus strains has become widespread in
hospitals and ICUs [26,27].
Of growing concern is the emergence of methicillin-resis-
tant Staphylococcus aureus (MRSA) in patients with no previ-
ous healthcare contact or apparent risk factors. Recently, a
prospective study from nine San Francisco-area medical cen-
tres found an annual incidence of community-onset MRSA
disease among San Francisco residents of 316 cases/100 000
population, as compared with 31 cases/100 000 population
for hospital-onset disease [28].
In 2003, Cosgrove et al. [29] conducted a meta-analysis to
summarize the impact of methicillin resistance on mortality in
cases of Staphylococcus aureus bacteraemia. All studies consid-
ered contained both absolute numbers and mortality rates for
patients with MRSA and methicillin-susceptible Staphylococcus
aureus (MSSA) bacteraemia. Data were analysed according to
the demographic characteristics of the patients, adjustment
for severity and comorbid illness, source of bacteraemia and
crude and adjusted ORs, and 95% CIs for in-hospital mortal-
ity. When the results were pooled with a random-effects
model, a signiﬁcant increase in mortality associated with
MRSA bacteraemia was evident (OR 1.93; 95% CI 1.54–2.42;
p <0.001). In subgroup analyses conducted to explore hetero-
geneity in the pooled analyses, mortality associated with
MRSA infection was consistently higher, with minimal hetero-
geneity or without signiﬁcant heterogeneity in each group.
Length of hospital stay and cost related to MRSA bactera-
emia, as compared with those related to MSSA bacteraemia,
were evaluated in two additional cohort studies [30,31].
A study by Cosgrove et al. [30] evaluated 346 patients admit-
ted to the Beth Israel Deaconess Medical Center in Boston
with clinically signiﬁcant Staphylococcus aureus bacteraemia
(96 case patients with MRSA infection and 252 control
patients with MSSA infection) between 1996 and 2000.
Among survivors, methicillin resistance was associated with a
signiﬁcant increase in the median length of hospital stay after
acquisition of infection (9 vs. 7 days for patients with MSSA
bacteraemia; p 0.045) and also with hospital costs after onset
of Staphylococcus aureus bacteraemia. MRSA bacteraemia was
an independent predictor of increase in both length of hospi-
talization (1.3-fold increase; p 0.016) and hospital costs (1.4-
fold increase; p 0.017). A second study [31] prospectively
evaluated 105 haemodialysis-dependent patients with Staphy-
lococcus aureus bacteraemia who were admitted to Duke
University Medical Center between 1996 and 2001. Thirty-
four patients with MRSA infections were compared with 70
patients with MSSA infections. The authors reported similar
results for the population of patients undergoing haemodialy-
sis and for the inpatient population in Boston; the adjusted
median length of hospital stay was longer (11 vs. 7 days;
p <0.001), and the adjusted median costs for the initial hos-
pitalization, and after 12 weeks, were also signiﬁcantly higher
for patients infected with MRSA.
Engemann et al. [32] evaluated clinical and economic out-
comes attributable to methicillin resistance in a retrospective
cohort study of patients with Staphylococcus aureus surgical
site infections primarily associated with cardiac or orthopae-
dic procedures. During the period 1994–2000, 121 patients
with a surgical site infection due to MRSA and 165 patients
with a surgical site infection due to MSSA were identiﬁed,
and another 193 uninfected patients, matched by type and
year of surgical procedure, were selected. The authors
reported an independent contribution of methicillin resis-
tance to increased mortality, prolonged length of hospitaliza-
tion, and increased hospital costs, which is consistent with
the ﬁndings for bacteraemia. The presence of MRSA in a sur-
gical wound increased the adjusted 90-day postoperative
mortality risk 3.4-fold, as compared with the presence of
MSSA (p 0.003), and 11.4-fold as compared with the absence
of infection (p <0.001) (Table 3).
A recent study from Canada addressing Staphylococcus
aureus bloodstream infections conﬁrmed the previous ﬁnd-
ings [32]. The authors reported a dramatic increase since
2004 in cases of MRSA bacteraemia, especially resulting from
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community-onset infections. Dialysis dependence, organ trans-
plantation, human immunodeﬁciency virus infection, cancer
and diabetes were the most important risk factors, and were
comparable for MSSA and MRSA bacteraemias. The overall
case-fatality rate was higher among individuals with MRSA
bacteraemia (39%) than among those with MSSA bacteraemia
(24%; p <0.0001) (Fig. 1).
Enterococci
Vancomycin-resistent enterococci (VRE) were ﬁrst isolated
almost 20 years ago [34], and have since become impor-
tant nosocomial pathogens for which there are limited
treatment options. VRE infections have been shown to
have a negative impact on both mortality and cost of hos-
pitalization [35–37].
In a meta-analysis, Diaz Granados et al. [38] addressed
the issue of whether vancomycin resistance is indepen-
dently associated with mortality among patients with
enterococcal bloodstream infection. Among 114 studies, 11
initially met the strict inclusion criteria. Finally, only nine
studies were eligible for analysis, with a total of 1614 epi-
sodes of enterococcal bloodstream infection (VRE, 683 epi-
sodes; vancomycin-susceptible enterococci, 931 episodes).
Four of the studies reported no signiﬁcant association
TABLE 3 Outcomes related to methicillin resistance in Staphylococcus aureus surgical site infections (SSIs) [32]
Comparison
Death Length of hospital stay after surgery Charges
Percentage
of subjects
who died OR p
Total no.
of days,
mean ME
No. of days
attributable
to MRSA p
US$,
mean ME
US$
attributable
to MRSA p
Control vs. MRSA SSI 11.4 <0.001 3.2 13.4 <0.001 2.2 41274 <0.001
Uninfected control subjects (n = 193) 2.1 6.1 34395
Patients with MRSA SSI (n = 121) 20.7 29.1 118414
MSSA SSI vs. MRSA SSI 3.4 0.003 1.2 2.6 0.11 1.2 13901 0.03
Patients with MSSA SSI (n = 165) 6.7 13.2 73165
Patients with MRSA SSI (n = 121) 20.7 29.1 118414
ME, multiplicative effect; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S.aureus
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FIG. 1. Mortality rate (no. of deaths per 100 000 population) associ-
ated with Staphylococcus aureus bacteraemia, Calgary Health Region,
2000–2006. MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus ([33], reprinted with per-
mission).
Bhavnani [39] 
Diaz Granados [40] 
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%
OR (random)
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FIG. 2. Meta-analysis plot using a random-
effects model. The dots represent the point
estimates for the measure of effect of each
study. The horizontal lines represent the
95% Cls for each study. The rhomboidal ﬁgure
represents the summary measure and 95% Cl.
The right column shows the numeric values
for each study and summary measure ([38],
reprinted with permission).
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between vancomycin resistance and mortality, and ﬁve
reported a signiﬁcant association. The point estimates for
all nine studies fell to the right side of 0-value (Fig. 2).
Patients with bacteraemia caused by VRE were more likely
to die than those with vancomycin-susceptible enterococci
bacteraemia (summary OR 2.52; 95% CI 1.9–3.4). Entero-
coccus faecium is more frequently associated with
vancomycin resistance than is Enterococcus faecalis; however,
several studies have demonstrated that an association
between mortality and vancomycin resistance is indepen-
dent of the species [38,47].
Taking into consideration all published data, we can
conclude that vancomycin resistance is an independent
predictor of death in patients with enterococcal bloodstream
infections.
Conclusions
The data presented in this review suggest that penicillin and
macrolide resistance is associated with a higher mortality
rate than penicillin and macrolide susceptibility in cases of
pneumococcal CAP and bacteraemia; infections due to MRSA
and VRE are also associated with higher mortality rates, pro-
longed length of hospital stay, and increased costs.
These data highlight the serious clinical consequences of
antimicrobial resistance among Gram-positive pathogens and
emphasize the importance of efforts to limit their emergence
and spread. Judicious use of antimicrobial drugs is necessary,
and several approaches have been suggested to improve anti-
microbial prescription practices by involving both patients
and physicians in educational efforts, as well as the pharma-
ceutical industry [1,48,49].
Acknowledgements
This article refers to the ESCMID Conference entitled ‘Fight-
ing infections due to MDR Gram positives’(Venice, May
2008), especially to the presentations of R. Cauder, P.
Courvalin, F. Vandenesch, G. Peters, W. Witte, J. Garau, C.
Brun-Buisson, J. Rello, R. Utili, E. Bouza, M. Bonten, W.
Kern, and M. Fallagas.
Transparency Declaration
H. M. Lode received funds and lecture fees from Bayer
Health Care, Sanoﬁ-Aventis, Pﬁzer, Janssen, Astellas, Wyeth
and GlaxoSmithKline.
References
1. Gyssens IC. All EU hands to the EU pumps: the Science Academies
of Europe (EASAC) recommend strong support of research to tackle
antibacterial resistance. Clin Microbiol Infect 2008; 14: 889–891.
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no
ESKAPE! An update from the Infectious Diseases Society of America.
Clin Infect Dis 2009; 48: 1–12.
3. McDonald LC. Trends in antimicrobial resistance in health care-asso-
ciated pathogens and effect on treatment. Clin Infect Dis 2006; 42:
S65–S71.
4. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among
methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;
46: S360–S367.
5. Sievert DM, Rudrik JT, Patel JB et al. Vancomycin-resistant Staphylo-
coccus aureus in the United States, 2002–2006. Clin Infect Dis 2008;
46: 668–674.
6. Cosgrove SE. The relationship between antimicrobial resistance and
patient outcomes: mortality, length of hospital stay, and health care
costs. Clin Infect Dis 2006; 42: S82–S89.
7. Kaye KS, Engemann JJ, Mozaffari E et al. Reference group choice and
antibiotic resistance outcomes. Emerg Infect Dis 2004; 10: 1125–1128.
8. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on
health and economic outcomes. Clin Infect Dis 2003; 36: 1433–1437.
9. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991–
2001.
10. File TM Jr, Tan JS, Boex JR. The clinical relevance of penicillin-resis-
tant Streptococcus pneumoniae: a new perspective. Clin Infect Dis 2006;
42: 798–800.
11. Pallares R, Lin˜ares J, Vadillo M et al. Resistance to penicillin and ceph-
alosporin and mortality from severe pneumococcal pneumonia in
Barcelona, Spain. N Engl J Med 1995; 333: 474–480.
12. Metlay JP. Antibacterial drug resistance: implications for the treat-
ment of patients with community-acquired pneumonia. Infect Dis Clin
North Am 2004; 18: 777–790.
13. Moroney JF, Fiore AE, Harrison LH et al. Clinical outcomes of bac-
teremic pneumococcal pneumonia in the era of antibiotic resistance.
Clin Infect Dis 2001; 33: 797–805.
14. Yu VL, Chiou CC, Feldman C et al. for the International Pneumococ-
cal Study Group. An international prospective study of pneumococcal
bacteremia: correlation with in vitro resistance, antibiotics adminis-
tered, and clinical outcome. Clin Infect Dis 2003;37:230–237.
15. Tleyjeh IM, Tlaygeh HM, Hejal R et al. The impact of penicillin resis-
tance on short-term mortality in hospitalized adults with pneumococ-
cal pneumonia: a systematic review and meta-analysis. Clin Infect Dis
2006; 42: 788–797.
16. Aspa J, Rajas O, Rodrı´guez de Castro F et al. Drug-resistant pneumo-
coccal pneumonia: clinical relevance and related factors. Clin Infect Dis
2004; 38: 787–798.
17. Lode HM. Managing community-acquired pneumonia: a European per-
spective. Respir Med 2007; 101: 1864–1873.
18. Henriques B, Kalin M, Ortqvist A et al. Molecular epidemiology
of Streptococcus pneumoniae causing invasive disease in 5 countries.
J Infect Dis 2000; 182: 833–839.
19. Musher DM, Dowell ME, Shortridge VD et al. Emergence of macro-
lide resistance during treatment of pneumococcal pneumonia. N Engl
J Med 2002; 346: 630–631.
20. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal
bacteremia in patients being treated with azithromycin and clarithro-
mycin. Clin Infect Dis 2000; 31: 1008–1011.
21. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic
treatment in patients with bacteremia due to erythromycin-resistant
Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–564.
216 Clinical Microbiology and Infection, Volume 15 Number 3, March 2009 CMI
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 212–217
22. Van Kerkhoven D, Peetermans WE, Verbist L et al. Breakthrough
pneumococcal bacteraemia in patients treated with clarithromycin or
oral beta-lactams. J Antimicrob Chemother 2003; 51: 691–696.
23. Daneman N, McGeer A, Green K et al. Toronto Invasive Bacterial
Diseases Network. Macrolide resistance in bacteremic pneumococcal
disease: implications for patient management. Clin Infect Dis 2006; 43:
432–438.
24. Mandell LA, Wunderink RG, Anzueto A et al. American Thoracic
Society. Infectious Diseases Society of America/American Thoracic
Society consensus guidelines on the management of community-
acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–S72.
25. Peterson LR. Penicillins for treatment of pneumococcal pneumonia:
does in vitro resistance really matter? Clin Infect Dis 2006; 42: 224–
233.
26. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylo-
cocci. Lancet 1963; 1: 904–907.
27. Grundmann H, Aires-de-Sousa M, Boyce J et al. Emergence and
resurgence of meticillin-resistant Staphylococcus aureus as a public-
health threat. Lancet 2006; 368: 874–885.
28. Liu C, Graber CJ, Karr M et al. A population-based study of the inci-
dence and molecular epidemiology of methicillin-resistant Staphylococ-
cus aureus disease in San Francisco, 2004–2005. Clin Infect Dis 2008;
46: 1637–1646.
29. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mor-
tality associated with methicillin-resistant and methicillin-susceptible
Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;
36: 53–59.
30. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resis-
tance in Staphylococcus aureus bacteremia on patient outcomes: mor-
tality, length of stay, and hospital charges. Infect Control Hosp
Epidemiol 2005; 26: 166–174.
31. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among
hemodialysis-dependent patients with methicillin-resistant or methicil-
lin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp
Epidemiol 2005; 26: 175–183.
32. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and eco-
nomic outcomes attributable to methicillin resistance among patients
with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;
1: 36.
33. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream
infections: risk factors, outcomes, and the inﬂuence of methicillin resis-
tance in Calgary, Canada, 2000–2006. J Infect Dis 2008; 198: 336–343.
34. Uttley AH, Collins CH, Naidoo J et al. Vancomycin-resistant entero-
cocci. Lancet 1988; 1: 57–58.
35. Edmond MB, Ober JF, Dawson JD et al. Vancomycin-resistant entero-
coccal bacteremia: natural history and attributable mortality. Clin
Infect Dis 1996; 23: 1234–1239.
36. Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter,
case-control study comparing risk factors, treatment, and outcome
for vancomycin-resistant and -susceptible enterococcal bacteremia.
Diagn Microbiol Infect Dis 2000; 36: 145–158.
37. Carmeli Y, Eliopoulos G, Mozaffari E et al. Health and economic out-
comes of vancomycin-resistant enterococci. Arch Intern Med 2002;
162: 2223–2228.
38. DiazGranados CA, Zimmer SM, Klein M et al. Comparison of mortal-
ity associated with vancomycin-resistant and vancomycin-susceptible
enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis
2005; 41: 327–333.
39. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on
mortality among patients with neutropenia and enterococcal blood-
stream infection. J Infect Dis 2005; 191: 588–595.
40. Garbutt JM, Ventrapragada M, Littenberg B. Association between
resistance to vancomycin and death in cases of Enterococcus faecium
bacteremia. Clin Infect Dis 2000; 30: 466–472.
41. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk
factors for vancomycin resistance and predictors of mortality. Infect
Control Hosp Epidemiol 1999; 20: 318–323.
42. Linden PK, Pasculle AW, Manez R et al. Differences in outcomes for
patients with bacteremia due to vancomycin-resistant Enterococcus
faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:
663–670.
43. Lodise TP, McKinnon PS, Tam VH et al. Clinical outcomes
for patients with bacteremia caused by vancomycin-resistant
enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34:
922–929.
44. Lucas GM, Lechtzin N, Puryear DW. Vancomycin-resistant and
vancomycin-susceptible enterococcal bacteremia: comparison of clini-
cal features and outcomes. Clin Infect Dis 1998; 26: 1127–1133.
45. Shay DK, Maloney SA, Montecalvo M et al. Epidemiology and mortal-
ity risk of vancomycin-resistant enterococcal bloodstream infections.
J Infect Dis 1995; 172: 993–1000.
46. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin
resistance and mortality rates in enterococcal bacteremia. a prospec-
tive multicenter study. Ann Intern Med 2001; 135: 484–492.
47. Chou YY, Lin TY, Lin JC et al. Vancomycin-resistant enterococcal
bacteremia: comparison of clinical features and outcome between
Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol
Infect 2008; 41: 124–129.
48. Wright GD, Sutherland AD. New strategies for combating multidrug-
resistant bacteria. Trends Mol Med 2007; 13: 260–267.
49. European Academies Science Advisory Council. Tackling antibacterial
resistance in Europe. AESAC policy report. London: The Royal Society,
2007. Available at: http://www.easac.eu/document.asp?id=31 (last
accessed 19 August 2008).
CMI Lode Resistant Gram-positive pathogens - clinical impact 217
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 212–217
